Tamoxifen Mechanism and Clinical Impact

Primary Mechanism of Action

The National Comprehensive Cancer Network recommends tamoxifen as a selective estrogen receptor modulator (SERM) that functions primarily by competitively binding to estrogen receptors in breast tissue, blocking estrogen's growth-promoting effects on breast cancer cells, with a relative risk reduction of 0.38 (95% CI, 0.28-0.50) for ER-positive tumors 1, 2
Tamoxifen reduces the risk of ER-positive breast cancer by 48-62% in high-risk women, according to the National Comprehensive Cancer Network 1, 3
The drug shows no benefit for ER-negative tumors (RR 1.31; 95% CI, 0.86-2.01), confirming its mechanism depends on estrogen receptor binding 1, 2

The National Comprehensive Cancer Network notes that medications that inhibit CYP2D6 (such as certain antidepressants) can reduce endoxifen formation and potentially decrease tamoxifen efficacy 4
Alternative medications with minimal CYP2D6 inhibition should be substituted when possible, as recommended by the National Comprehensive Cancer Network 4

Tamoxifen acts as an estrogen agonist in the endometrium, increasing endometrial proliferation and cancer risk (RR 2.5-4.0), according to the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network states that the benefits of tamoxifen continue after cessation of treatment, while many side effects diminish or disappear 4, 6
The difference in ER-positive breast cancer incidence between tamoxifen and placebo became significant only in the post-treatment period (after 8 years) in the IBIS-I trial, suggesting tamoxifen may induce long-lasting changes in breast tissue responsiveness to estrogen 7, 8